Neurocrine Biosciences Completes Strategic Acquisition, Secures Robust Credit Facility, and Advances Clinical Portfolio
Neurocrine Biosciences Inc. (NASDAQ: NRTH) announced on May 18 2026 the successful completion of its acquisition of Soleno Therapeutics, Inc. (OTC: SOLN), a transaction that will expand Neurocrine’s drug‑development pipeline and reinforce its position in the neuro‑psychiatric therapeutics market. The acquisition was executed via a tender offer and subsequent merger, in which the company’s subsidiary, Sigma Merger Sub, Inc., offered to purchase all outstanding Soleno shares at a cash price. The offer was accepted by the majority of Soleno shareholders, and the merger closed immediately, resulting in Soleno becoming a wholly owned subsidiary of Neuro‑Biosciences.
Transaction Structure and Valuation
The transaction is valued at approximately $2.9 billion and was financed entirely from Neuro‑Biosciences’ available cash balance. By leveraging internal liquidity rather than external debt, the company preserves flexibility for future capital‑intensive initiatives, such as late‑stage clinical development and regulatory approval processes. The use of a cash‑only structure also signals confidence in the company’s balance‑sheet strength and reduces dilution risk for existing shareholders.
Credit Facility Enhancement
In tandem with the acquisition, Neuro‑Biosciences closed a five‑year, $1 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A., and a consortium of leading lenders. The facility offers flexible borrowing terms with a variable interest rate linked to a benchmark plus margin, and it is not subject to amortization. An initial draw of $600 million was executed on the closing date to fund working‑capital and growth requirements. The credit line provides a strategic financial buffer, enabling the company to pursue additional acquisitions, support ongoing clinical programs, and meet short‑term liquidity needs without compromising long‑term debt capacity.
Shareholder Activity
A Form 4 filing disclosed that Neuro‑Biosciences director Richard F. Pop increased his direct ownership of the company’s common stock to nearly 50 000 shares. The transaction involved the purchase of 15 000 shares and the sale of 15 000 shares, resulting in a net gain in holdings. The filing also noted the exercise of a non‑qualified stock option that expired on May 20 2026. This activity reflects ongoing executive confidence in the company’s strategic direction and valuation prospects.
Clinical Development Highlights
Neuro‑Biosciences issued a news release detailing real‑world evidence on the effectiveness of its drug INGREZZA® (valbenazine) in patients with mild tardive dyskinesia. The study, presented at the American Psychiatric Association meeting in San Francisco, demonstrated that most patients experienced reduced involuntary movements within four weeks of treatment. Functional outcomes, such as independence and daily activity performance, also improved. These findings align with previous clinical studies and reinforce INGREZZA’s therapeutic profile for this patient population.
Strategic Implications
The acquisition of Soleno Therapeutics expands Neuro‑Biosciences’ portfolio of neuro‑psychiatric assets and positions the company to capitalize on growing demand for targeted treatments in movement disorders. The combined entity benefits from complementary scientific expertise, robust pipeline assets, and a diversified commercial footprint. By securing a sizeable revolving credit facility, Neuro‑Biosciences maintains operational agility, enabling rapid response to emerging market opportunities and regulatory milestones.
From a financial standpoint, the transaction’s cash‑only structure preserves debt capacity, while the credit line offers a low‑cost, flexible source of working‑capital financing. This dual approach balances risk and reward, providing a solid foundation for future growth initiatives.
Overall, the completion of the Soleno acquisition, the establishment of a sizable credit facility, and the publication of positive real‑world data collectively strengthen Neuro‑Biosciences’ competitive positioning. The company is poised to leverage these developments to accelerate product commercialization, enhance shareholder value, and drive long‑term innovation in the neuro‑psychiatric therapeutics sector.
